{"dataset":"drug-shortages","sample":[{"id":"FDA-0409-2596-05-current","country":"US","authority":"US Food and Drug Administration (FDA)","product":"Midazolam Hydrochloride","active_substance":"Midazolam Hydrochloride","strength":"50 mg/10 mL (5 mg/mL)","form":"Injection","presentation":"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL)","product_code":"NDC 0409-2596-05","holder":"Hospira, Inc., a Pfizer Company","status":"current","status_published":"Current","availability":"Available","start_date":"2020-04-02","expected_resolution":null,"expected_resolution_date":null,"resolved_date":null,"discontinued_date":null,"reason":null,"therapeutic_areas":["Anesthesia","Neurology"],"atc_code":null,"alternatives_available":null,"updated":"2026-10-29","language":"en","url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%220409-2596-05%22","verification":"official-publication","paid_placement":false,"source_id":"openfda-drug-shortages","source_url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%220409-2596-05%22","retrieved_at":"2026-10-31T05:53:40.925222+00:00"},{"id":"EMA-human-normal-immunoglobulins","country":"EU","authority":"European Medicines Agency (EMA)","product":"Human normal immunoglobulins","active_substance":"human normal immunoglobulins","strength":null,"form":"Solution for injection/infusion","presentation":null,"product_code":null,"holder":null,"status":"current","status_published":"Shortage ongoing","availability":null,"start_date":"2024-06-03","expected_resolution":"March 2027","expected_resolution_date":null,"resolved_date":null,"discontinued_date":null,"reason":null,"therapeutic_areas":["Primary Immunodeficiency Diseases","Immunologic Deficiency Syndromes"],"atc_code":null,"alternatives_available":"Yes","updated":"2026-09-22","language":"en","url":"https://www.ema.europa.eu/en/medicines/human/shortages/human-normal-immunoglobulins","verification":"official-publication","paid_placement":false,"source_id":"ema-shortages-json","source_url":"https://www.ema.europa.eu/en/documents/report/shortages-output-json-report_en.json","retrieved_at":"2026-10-31T05:53:46.351141+00:00"},{"id":"FDA-66758-087-70-discontinued","country":"US","authority":"US Food and Drug Administration (FDA)","product":"Cipro","active_substance":"Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops","strength":"0.2% base, 1%","form":null,"presentation":"Cipro, Otic Suspension/Drops, 0.2% base, 1%","product_code":"NDC 66758-087-70","holder":"Sandoz Inc.","status":"discontinued","status_published":"To Be Discontinued","availability":null,"start_date":"2026-10-30","expected_resolution":null,"expected_resolution_date":null,"resolved_date":null,"discontinued_date":"2026-10-30","reason":"Discontinuation of the manufacture of the drug","therapeutic_areas":["Anti-Infective"],"atc_code":null,"alternatives_available":null,"updated":"2026-10-30","language":"en","url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%2266758-087-70%22","verification":"official-publication","paid_placement":false,"source_id":"openfda-drug-shortages","source_url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%2266758-087-70%22","retrieved_at":"2026-10-31T05:53:40.925222+00:00"},{"id":"FDA-0409-1752-50-current","country":"US","authority":"US Food and Drug Administration (FDA)","product":"Marcaine with Epinephrine","active_substance":"Bupivacaine Hydrochloride, Epinephrine Bitartrate","strength":"Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000)","form":"Injection","presentation":"Marcaine with Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000)","product_code":"NDC 0409-1752-50","holder":"Hospira, Inc., a Pfizer Company","status":"current","status_published":"Current","availability":"Limited Availability","start_date":"2018-02-20","expected_resolution":"December 2026","expected_resolution_date":null,"resolved_date":null,"discontinued_date":null,"reason":"Other","therapeutic_areas":["Anesthesia"],"atc_code":null,"alternatives_available":null,"updated":"2026-10-29","language":"en","url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%220409-1752-50%22","verification":"official-publication","paid_placement":false,"source_id":"openfda-drug-shortages","source_url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%220409-1752-50%22","retrieved_at":"2026-10-31T05:53:40.925222+00:00"},{"id":"FDA-61703-350-38-current","country":"US","authority":"US Food and Drug Administration (FDA)","product":"Methotrexate Sodium","active_substance":"Methotrexate Sodium","strength":"50 mg/2 mL (25 mg/mL)","form":"Injection","presentation":"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL)","product_code":"NDC 61703-350-38","holder":"Hospira, Inc., a Pfizer Company","status":"current","status_published":"Current","availability":"Available","start_date":"2023-03-13","expected_resolution":null,"expected_resolution_date":null,"resolved_date":null,"discontinued_date":null,"reason":null,"therapeutic_areas":["Rheumatology","Oncology"],"atc_code":null,"alternatives_available":null,"updated":"2026-10-29","language":"en","url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%2261703-350-38%22","verification":"official-publication","paid_placement":false,"source_id":"openfda-drug-shortages","source_url":"https://api.fda.gov/drug/shortages.json?search=package_ndc:%2261703-350-38%22","retrieved_at":"2026-10-31T05:53:40.925222+00:00"}],"feedback":{"message":"Not buying? Tell us why in one free call: we use this feedback to provide a better offering. Do not include personal data.","method":"POST","endpoint":"https://agentdatafeed.com/v1/feedback","mcp_tool":"send_feedback","body":{"type":"no_purchase","dataset":"drug-shortages","reason":"no_budget | cost_too_high | dataset_usability_uncertain | other","comment":"optional free text, max 500 characters (required when reason is other)"}}}